ArticlesArchiveAboutEditorial BoardAuthor Guidelines
Call for papersThe 2026 special issue on Climate & Health is open for submissions.Learn more
JCT is an international journal dedicated to the latest advancements in cancer therapy. The goal of this journal is to provide a platform for doctors and academicians all over the world to promote, share, and discuss various new issues and developments in cancer related problems. All manuscripts must be prepared in En…
Shilpa Sharma, Gurudutta Gangenahalli
The tyrosine kinase receptor III, c-Kit/stem cell factor receptor and its ligand, human stem cell factor (huSCF) are the predominant regulator of mitogenesis in the hematopoietic stem and progenitor cells. However, gain-of-function mutations alter c-Kit auto-…
P. S. Kadam Amare, S. Kakade, K. Chopra, M. Sengar, H. Menon, H. Jain, B. Bagal, P. G. Subramanian, S. Gujral
Background: Various genetic technologies have been employed in the identification of genomic complexity and refinement of prognostic classification of clinically heterogeneous disease of chronic lymphocytic leukemia (CLL). Objective: The present study of inte…
Kirsten H. Walen
In a series of publications a special, tetraploid diplochromosomal division system to only two types of progeny cells (4n/4C/G1 and 2n/4C para-diploid) has been suggested to initiate preneoplasia that can lead to a cancerous pathway. Colorectal and other pren…
Behnaz Seyfi, Anand P. Santhanam, Olusegun J. Ilegbusi
A biomechanical model is developed and validated for breathing-induced deformation of human lung. Specifically, a subject-specific poro-elastic lung model is used to predict the displacement over the breathing cycle and compared with displacement derived from…
Francesco Pantano, Giulia Ribelli, Michele Iuliani, Marco Fioramonti, Mark Leakos, Alice Zoccoli, Daniele Santini, Giovanni Muto, Giuseppe Tonini
Prostate cancer (PCa) is the second leading cause of cancer death in men. Despite initial responses, almost all patients progress to castration-resistant prostate cancer (CRPC). Over the past decade, increased understanding of the mechanisms that drive resist…
G. P. Talwar, Jagdish C. Gupta, M. Diwan, J. Frick, S. K. Sharma, S. N. Wadhwa, R. M. Gupta, S. K. Gupta, Shilpi Purswani, Hemant K. Vyas
This review describes briefly the beneficial use of two vaccines developed by us for treatment of cancers. The vaccine against Luteinizing Hormone Releasing Hormone (LHRH) is effective in carcinoma of prostate as well as in breast cancers dependent on androge…
Toru Akiyama, Kazuo Saita, Hirotaka Chikuda, Hiromasa Horiguchi, Kiyohide Fushimi, Hideo Yasunaga
Introduction: Reducing the in-hospital post-chemotherapy mortality rate in patients with malignant musculoskeletal tumors is important for improving treatment outcome. This study aimed to investigate the risk factors associated with in-hospital post-chemother…
Philippe R. Pouillart, Elodie Gidoin-Dewulf, Cécile Foissy, Eva Joubert, Magali Thieulent, Odile Compère, Sif Bendjaballah
Cancer cachexia and treatment-induced side effects can contribute to deterioration in nutritional status in patients declining the quality of life and survival rates. Culinary practices may provide new strategies to minimize the symptoms. NEODIA (learning to…
Ahmed El Sayed Fathalla, Marwa Nabil Abd El Hafez
Background: Carcinoma of the male breast is relatively a rare disease accounting for about 1% of all cancer in men. Its treatments are based mainly on those of Female Breast Cancer (BCF). Materials and Methods: This is a single institution retrospective study…
Elisabetta Malangone-Monaco, Tony Okoro, Beata Korytowsky, Amy Stanford, Stephen Johnston, William Johnson, Sigrun Hallmeyer
As the treatment landscape for advanced melanoma continues to evolve, it is critical to focus on unmet needs and understand the cost of therapy. While Ipilimumab (IPI), an immunotherapy indicated for unresectable advanced melanoma, has been a mainstay of 1 st…
No articles in this issue.
JCT is an international journal dedicated to the latest advancements in cancer therapy. The goal of this journal is to provide a platform for doctors and academicians all over the world to promote, share, and discuss various new issues and developments in cancer related problems. All manuscripts must be prepared in En… All articles are open access under a CC BY 4.0 licence, with authors retaining copyright.
Authors submit their manuscript, metadata, and declarations through the portal. There is no submission fee.
The editorial office screens the manuscript for scope, completeness, and formatting before assigning a handling editor.
At least two independent reviewers evaluate the manuscript under single-blind review. Where revisions are required, authors respond point by point.
On acceptance the article processing charge is invoiced and the CC BY 4.0 copyright handover is signed.
The article is copyedited, typeset, and given a DOI, then publishes open access with a permanent link.
Manuscripts must be original and not under consideration elsewhere. Submit in Microsoft Word or LaTeX with figures at 300 dpi minimum. Structure research articles as Abstract, Introduction, Methods, Results, Discussion, and References.
Use the journal's numbered (Vancouver) reference style. Cite sources consecutively in the order they appear, and ensure every reference is complete and retrievable.
Declare all funding sources, conflicts of interest, and ethical approvals (including informed consent and animal-care statements where applicable).